Does the media favor AXSM or MLYS?

In the previous week, Axsome Therapeutics had 7 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 11 mentions for Axsome Therapeutics and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.04 beat Axsome Therapeutics' score of 0.74 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MLYS or RDY?

Mineralys Therapeutics presently has a consensus price target of $48.80, suggesting a potential upside of 68.80%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Mineralys Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mineralys Therapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media refer more to MLYS or RDY?

In the previous week, Mineralys Therapeutics had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for Mineralys Therapeutics and 2 mentions for Dr. Reddy's Laboratories. Mineralys Therapeutics' average media sentiment score of 1.04 beat Dr. Reddy's Laboratories' score of 0.98 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, BLTE or MLYS?

Belite Bio is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.73 N/A Mineralys Therapeutics N/A N/A -$154.65M -$4.24 N/A

Is BLTE or MLYS more profitable?

Belite Bio's return on equity of -11.84% beat Mineralys Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -11.84% -11.62% Mineralys Therapeutics N/A -57.97% -54.15%

Does the media prefer BLTE or MLYS?

In the previous week, Belite Bio had 11 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 15 mentions for Belite Bio and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.04 beat Belite Bio's score of 0.33 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MLYS or LNTH?

In the previous week, Lantheus had 3 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 7 mentions for Lantheus and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.04 beat Lantheus' score of 0.98 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Mineralys Therapeutics (MLYS) Competitors

$28.91 -0.04 (-0.14%)

Closing price 04:00 PM Eastern

Extended Trading

$28.90 -0.02 (-0.05%)

As of 04:10 PM Eastern

Compare

MLYS vs. AXSM, RDY, CRNX, BLTE, and LNTH

Should you buy Mineralys Therapeutics stock or one of its competitors? Mineralys Therapeutics's main competitors and comparable companies include Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), Crinetics Pharmaceuticals (CRNX), Belite Bio (BLTE), and Lantheus (LNTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Mineralys Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Mineralys Therapeutics (NASDAQ:MLYS) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Mineralys Therapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	16.74	-$183.17M	-$3.75	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A

Mineralys Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -24.68%. Mineralys Therapeutics' return on equity of -57.97% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Mineralys Therapeutics	N/A	-57.97%	-54.15%

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Axsome Therapeutics currently has a consensus price target of $267.60, suggesting a potential upside of 31.13%. Mineralys Therapeutics has a consensus price target of $48.80, suggesting a potential upside of 68.80%. Given Mineralys Therapeutics' higher possible upside, analysts plainly believe Mineralys Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Mineralys Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Axsome Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 7 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 11 mentions for Axsome Therapeutics and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.04 beat Axsome Therapeutics' score of 0.74 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Axsome Therapeutics beats Mineralys Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Dr. Reddy's Laboratories?

Mineralys Therapeutics (NASDAQ:MLYS) and Dr. Reddy's Laboratories (NYSE:RDY) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Mineralys Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-57.97%	-54.15%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Mineralys Therapeutics presently has a consensus price target of $48.80, suggesting a potential upside of 68.80%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Mineralys Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Dr. Reddy's Laboratories has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A
Dr. Reddy's Laboratories	$331.19B	0.03	$456M	$0.44	26.23

Mineralys Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market.

In the previous week, Mineralys Therapeutics had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for Mineralys Therapeutics and 2 mentions for Dr. Reddy's Laboratories. Mineralys Therapeutics' average media sentiment score of 1.04 beat Dr. Reddy's Laboratories' score of 0.98 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Mineralys Therapeutics beats Dr. Reddy's Laboratories on 8 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, Mineralys Therapeutics had 3 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 4 mentions for Mineralys Therapeutics and 1 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.60 beat Mineralys Therapeutics' score of 1.04 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Crinetics Pharmaceuticals	Very Positive
Mineralys Therapeutics	Positive

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Mineralys Therapeutics has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A

Crinetics Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

Crinetics Pharmaceuticals currently has a consensus target price of $81.00, suggesting a potential downside of 4.65%. Mineralys Therapeutics has a consensus target price of $48.80, suggesting a potential upside of 68.80%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Mineralys Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Mineralys Therapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Crinetics Pharmaceuticals' return on equity of -44.22% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Mineralys Therapeutics	N/A	-57.97%	-54.15%

Summary

Mineralys Therapeutics beats Crinetics Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Belite Bio currently has a consensus target price of $218.73, suggesting a potential upside of 29.09%. Mineralys Therapeutics has a consensus target price of $48.80, suggesting a potential upside of 68.80%. Given Mineralys Therapeutics' higher probable upside, analysts clearly believe Mineralys Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Mineralys Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Belite Bio's return on equity of -11.84% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Mineralys Therapeutics	N/A	-57.97%	-54.15%

Belite Bio has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

In the previous week, Belite Bio had 11 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 15 mentions for Belite Bio and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.04 beat Belite Bio's score of 0.33 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mineralys Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Belite Bio is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A

Summary

Belite Bio beats Mineralys Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Lantheus?

Mineralys Therapeutics (NASDAQ:MLYS) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Lantheus has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A
Lantheus	$1.54B	4.26	$233.56M	$4.14	24.33

Lantheus has a net margin of 17.69% compared to Mineralys Therapeutics' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-57.97%	-54.15%
Lantheus	17.69%	28.10%	14.35%

Mineralys Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market.

In the previous week, Lantheus had 3 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 7 mentions for Lantheus and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.04 beat Lantheus' score of 0.98 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Mineralys Therapeutics currently has a consensus target price of $48.80, indicating a potential upside of 68.80%. Lantheus has a consensus target price of $108.11, indicating a potential upside of 7.33%. Given Mineralys Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Mineralys Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Lantheus beats Mineralys Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Mineralys Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLYS vs. The Competition

Export

Metric	Mineralys Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.56B	$12.45B	$7.17B	$14.34B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-6.82	792.11	273.41	25.34
Price / Sales	N/A	763.33	674.93	98.63
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	3.54	10.40	10.38	6.20
Net Income	-$154.65M	$2.83B	$3.49B	$358.18M
7 Day Performance	-7.10%	-3.31%	-2.20%	-1.61%
1 Month Performance	12.75%	0.77%	-0.39%	-3.63%
1 Year Performance	-20.16%	3.62%	19.16%	5.94%

Mineralys Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLYS Mineralys Therapeutics	2.4786 of 5 stars	$28.91 -0.1%	$48.80 +68.8%	-22.0%	$2.56B	N/A	N/A	76	Positive News
AXSM Axsome Therapeutics	3.7976 of 5 stars	$208.25 +0.8%	$267.60 +28.5%	+82.9%	$10.90B	$776.57M	N/A	380
RDY Dr. Reddy's Laboratories	1.7291 of 5 stars	$11.88 -0.7%	N/A	-18.7%	$9.91B	$3.58B	26.99	27,527
CRNX Crinetics Pharmaceuticals	1.5345 of 5 stars	$84.95 flat	$81.00 -4.6%	N/A	$9.01B	$7.70M	N/A	210	Positive News
BLTE Belite Bio	3.5599 of 5 stars	$195.28 +0.9%	$217.45 +11.4%	+149.0%	$7.86B	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLYS) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. AXSM, RDY, CRNX, BLTE, and LNTH

How does Mineralys Therapeutics compare to Axsome Therapeutics?

Summary

How does Mineralys Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Mineralys Therapeutics compare to Crinetics Pharmaceuticals?

Summary

How does Mineralys Therapeutics compare to Belite Bio?

Summary

How does Mineralys Therapeutics compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. AXSM, RDY, CRNX, BLTE, and LNTH

How does Mineralys Therapeutics compare to Axsome Therapeutics?

Which has better valuation and earnings, AXSM or MLYS?

Is AXSM or MLYS more profitable?

Do insiders & institutionals hold more shares of AXSM or MLYS?

Do analysts recommend AXSM or MLYS?

Which has more volatility & risk, AXSM or MLYS?

Does the media favor AXSM or MLYS?

Summary

How does Mineralys Therapeutics compare to Dr. Reddy's Laboratories?

Is MLYS or RDY more profitable?

Do analysts rate MLYS or RDY?

Which has higher earnings and valuation, MLYS or RDY?

Which has more volatility & risk, MLYS or RDY?

Does the media refer more to MLYS or RDY?

Do insiders and institutionals hold more shares of MLYS or RDY?

Summary

How does Mineralys Therapeutics compare to Crinetics Pharmaceuticals?

Does the media prefer CRNX or MLYS?

Do insiders and institutionals hold more shares of CRNX or MLYS?

Which has higher valuation & earnings, CRNX or MLYS?

Which has more volatility & risk, CRNX or MLYS?

Do analysts recommend CRNX or MLYS?

Is CRNX or MLYS more profitable?

Summary

How does Mineralys Therapeutics compare to Belite Bio?

Do analysts rate BLTE or MLYS?

Is BLTE or MLYS more profitable?

Which has more risk & volatility, BLTE or MLYS?

Does the media prefer BLTE or MLYS?

Do institutionals and insiders hold more shares of BLTE or MLYS?

Which has better earnings & valuation, BLTE or MLYS?

Summary

How does Mineralys Therapeutics compare to Lantheus?

Which has higher valuation & earnings, MLYS or LNTH?

Is MLYS or LNTH more profitable?

Which has more risk and volatility, MLYS or LNTH?

Does the media favor MLYS or LNTH?

Do insiders and institutionals have more ownership in MLYS or LNTH?

Do analysts rate MLYS or LNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools